Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Guozhu Ning *Innovation Centre of Ministry of Education for Development and Diseases, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.ORCID https://orcid.org/0000-0003-3392-3007
Yu Lin *School of Pharmacy, Qiqihar Medical University, Qiqihar, China.
Haixia MaInstitute State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Stem Cell and Regeneration, Beijing Institute of Stem Cell and Regenerative Medicine, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Jiaqi ZhangInstitute State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Stem Cell and Regeneration, Beijing Institute of Stem Cell and Regenerative Medicine, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Liping YangInnovation Centre of Ministry of Education for Development and Diseases, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Zhengyu LiuInnovation Centre of Ministry of Education for Development and Diseases, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Lei LiInstitute State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Stem Cell and Regeneration, Beijing Institute of Stem Cell and Regenerative Medicine, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.ORCID https://orcid.org/0000-0001-5478-5681
Xinyu HeInnovation Centre of Ministry of Education for Development and Diseases, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.ORCID https://orcid.org/0009-0006-0829-9125
Qiang WangInnovation Centre of Ministry of Education for Development and Diseases, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.ORCID https://orcid.org/0000-0002-8735-8771
Funding
National Key Research and Development Program of China 2018YFA0800200National Key Research and Development Program of China 2020YFA0804000National Natural Science Foundation of China 32025014National Natural Science Foundation of China 32330029
6 · The paper itself
Abstract
Breast carcinoma amplified sequence 2 (BCAS2), a core component of the hPrP19 complex, plays crucial roles in various physiological and pathological processes. However, whether BCAS2 has functions other than being a key RNA-splicing regulator within the nucleus remains unknown. Here, we show that BCAS2 is essential for primitive hematopoiesis in zebrafish and mouse embryos. The activation of Wnt/β-catenin signaling, which is required for hematopoietic progenitor differentiation, is significantly decreased upon depletion of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
BCAS2 promotes primitive hematopoiesis by sequestering β-catenin within the nucleus. · full record | OpenQuestion